Key points from article :
A new clinical trial led by Dr. Ashish Sarraju from the Cleveland Clinic and published in The Lancet has shown that combining an existing cholesterol drug with a new, investigational one can significantly lower LDL (“bad”) cholesterol levels—by nearly 49%—in people at high risk of heart disease.
Researchers tested a fixed-dose combination of ezetimibe (an approved drug) and obicetrapib (a new drug not yet on the market) in 407 adults whose LDL cholesterol levels remained high despite other medications. After just 84 days of daily treatment, those who received the combination therapy experienced a 48.6% drop in LDL levels compared to placebo. Obicetrapib alone reduced LDL by nearly 32%.
The treatment was generally well tolerated, and experts believe this dual-drug approach could offer a powerful new option for patients whose cholesterol remains stubbornly high—even with standard therapies like statins. If approved by regulators, this combination could help many people with cardiovascular disease reach safer cholesterol levels.
